MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

High yield biosynthesis of 6-hydroxynicotinic acid, an intermediate for pharmaceuticals, agrochemicals and feed additives

Consejo Superior de Investigaciones Cientificas, CSIC (Spanish National Research Council)
A method to generate microorganisms showing high-yield synthesis of 6-hydroxynicotinic acid (6-HNA, a precursor of pharmaceuticals, agrochemicals and feed) based on genetic engineering

Full description

Background

The production of modern insecticides (e.g. imadacloprid-related), some feed additives and pharmaceuticals (e.g. compounds used for treatment of congestive heart failure, an antilipolytic drug) involves 6-hydroxynicotinic acid (6-HNA).

Since chemical synthesis of 6-HNA is inefficient and expensive due to the formation of by-products, most industrial processes are based on fermentation with bacteria naturally synthesizing 6-HNA. Nevertheless, these bacteria strains also degrade 6-HNA and thus a high concentration of nicotinic acid (the 6-HNA precursor) is added to inhibit this degradation. Besides requiring additional precursor to act as an inhibitor (i.e. not to productive pathways), specific continuous control to ensure a concentration higher than 1% nicotinic acid must be implemented. On the other hand residual 6-HNA degradation is always present even at these concentrations.

Technology

Our approach is based upon a genetically transformed microorganism capable of synthesizing 6-HNA but unable to degrade it. This is achieved by two alternative ways:1) transferring the two bacterial genes for 6-HNA synthesis to a microorganism that is not naturally capable of this synthesis.2) disrupting the expression of the gene involved in 6-HNA degradation in a microorganism that is naturally capable of synthesizing 6-HNA.

This novel approach has been applied to different Pseudomonas strains. A 98-99% yield was consistently reached in all cases.

Main features and advantages

  • Higher production yield (close to 100%).
  • Lower costs (no need for additional substrate aimed at unproductive effects).
  • Easier control (degradation of 6-HNA does not need to be continuously inhibited, since no degrading enzyme is present).
  •  There is no poisoning by accumulation of by-products produced by degradation of 6-HNA.
  • Straightforward adaptability to current industrial processes and equipments.

Patent information

Spanish and PCT (“International”) applications filed.

Type of business relationship sought

License agreement + Technical support

Licensing contact

Dr Jose Pablo Zamorano
Area Coordinator - Life Sciences
IP Commercialization

Contact directly

Company details

Consejo Superior de Investigaciones Cientificas, CSIC (Spanish National Research Council)

Spanish public research organisation with 126 centres covering all knowledge areas and highly active in collaborating with the industry.

View profile

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioPartnering America
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us